CAR-T Therapy & Antibody Engineering: A Convergence of Immunotherapy Innovations, Advanced Cell Engineering

In recent years, the landscape of cancer treatment has been profoundly reshaped by the emergence of immunotherapy strategies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy and antibody engineering. These modalities represent two of the most promising fronts in the fight against cancer, leveraging the body’s immune system to recognize and destroy malignant cells. While CAR-T therapy involves reprogramming the patient's T cells to target tumor cells, antibody engineering focuses on creating highly specific antibodies that can bind to cancer-specific antigens and recruit immune effector functions. This article explores the interplay between these two technologies, highlighting how they complement each other and could potentially integrate to offer more effective cancer treatment solutions.